annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 49D Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab:
Long-term follow-up of 179 patients with metastatic melanoma. (Abstract
#8544)
P. A. Prieto, J. C. Yang, R. M. Sherry, M. S. Hughes, U. S. Kammula, D. E. White,
C. L. Levy, S. A. Rosenberg, G. Q. Phan
Brd. 49E Sunitinib therapy for metastatic melanomas with KIT aberrations. (Abstract
#8545)
D. R. Minor, S. O’Day, M. Kashani-Sabet, A. Daud, Z. Salman, B. Bastian
Brd. 49F Preclinical analyses of a new gamma-secretase inhibitor targeting notch
signaling in melanoma. (Abstract #8546)
L. Poliseno, C. T. Huynh, M. F. Segura, R. Medicherla, S. Menendez, A. E. Rose,
A. C. Pavlick, J. Boylan, I. Osman, E. Hernando
Brd. 49G Clinical outcome following therapeutic vaccination with autologous mRNA
electroporated dendritic cell (DC) vaccines in patients with advanced
melanoma. (Abstract #8547)
S. Wilgenhof, A. M. Van Nuffel, D. Benteyn, J. Corthals, C. Heirman, L. Pierret,
A. De Coninck, A. Bonehill, K. Thielemans, B. Neyns
Brd. 49H Clinico-pathologic correlates of BRAF mutation status in 207 consecutive
patients with metastatic melanoma. (Abstract #8548)
G. V. Long, A. M. Menzies, A. Nagrial, L. Haydu, A. L. Hamilton, G. Mann,
T. M. Hughes, J. F. Thompson, R. A. Scolyer, R. Kefford
Brd. 50A A predictive model to determine the likelihood of positive sentinel lymph
node biopsy in thin melanomas. (Abstract #8549)
S. S. Venna, S. Thummala, M. Nosrati, S. P. Leong, J. R. Miller III, R. Sagebiel,
M. Kashani-Sabet
Brd. 50B Phase III, randomized, double-blind study of elesclomol and paclitaxel
versus paclitaxel alone in stage IV metastatic melanoma (MM): 1-year OS
update. (Abstract #8550^)
V. M. Vukovic, A. Hauschild, A. M. Eggermont, S. O’Day
Brd. 50C Correlation of stem cell marker nestin expression on circulating melanoma
cells with extension of disease and survival. (Abstract #8551)
A. Fusi, U. Reichelt, A. Busse, S. Ochsenreither, A. Rietz, M. Maisel, U. Keilholz
Brd. 50D Phase I/II trial of association of sorafenib in combination with temozolomide
in patients with metastatic melanoma: Looking for predictive markers of
efficacy. (Abstract #8552)
C. Robert, N. Chaput, N. Lassau, A. Auperin, S. Koscielny, E. Hollville, V. Lazar,
L. Lacroix, J. Soria, C. Mateus
Brd. 50E The use of integrative genomics to define molecular signatures of melanoma
histologic subtypes. (Abstract #8553)
A. E. Rose, L. Poliseno, A. Pearlman, J. Wang, H. Ostrer, F. Darvishian,
R. L. Shapiro, A. C. Pavlick, E. Hernando, I. Osman
Brd. 50F Preclinical analysis of targeting miR-182 against melanoma liver metastasis.
(Abstract #8554)
C. T. Huynh, M. F. Segura, S. Menendez, F. Darvishian, E. G. Marcusson,
E. Hernando
Brd. 50G Tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein
in combination with DTIC in chemotherapy-naive stage IV melanoma
patients. (Abstract #8555)
B. Weide, T. K. Eigentler, A. Romanini, F. G. De Braud, L. Giovannoni, D. Neri,
H. Menssen, C. Garbe
Brd. 50H Patterns of recurrence in 208 patients with Merkel cell carcinoma.
(Abstract #8556)
T. L. Bowles, M. I. Ross, M. S. Kies, V. Prieto, J. Myers, J. N. Cormier,
P. F. Mansfield, J. E. Lee, J. E. Gershenwald
224